Drugs / CT071
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06407947 | Jun 2024 → Jun 2027 expected | plasma cell myeloma | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05838131 | Apr 2023 → Jul 2025 overdue | plasma cell leukemia, plasma cell myeloma | Shanghai Changzheng Hospital | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06333509 | Apr 2024 → Jun 2027 expected | plasma cell leukemia, plasma cell myeloma | CARsgen Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-10-08 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology carsgen.com ↗
With a median follow-up of 10.71 months (IQR 6.13-12.02), the objective response rate (ORR) was 100% (95%CI, 83.2-100). |
| 2025-06-16 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Presents Results of GPRC5D CAR-T CT071 at EHA 2025 carsgen.com ↗
The overall response rate (ORR) was 100%, including stringent complete response (sCR) rate of 70% (7/10). |
| 2025-04-28 | Puma Biotechnology, Inc. | Results Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 pumabiotechnology.com ↗
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025. |
| 2024-11-01 | CARsgen Therapeutics Co., Ltd. | Regulatory CARsgen ® U.S. Clinical Holds Lifted by FDA carsgen.com ↗ |
| 2024-10-09 | CARsgen Therapeutics Co., Ltd. | Regulatory CARsgen ® Submitted Application to Request Lifting Clinical Holds to FDA carsgen.com ↗
The Company has submitted the complete response letters to request lifting the clinical holds for zevorcabtagene autoleucel, satricabtagene autoleucel and CT071 to FDA on October 4, 2024. |
| 2024-06-17 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Presents Phase II Results on Zevorcabtagene Autoleucel and First-in-human CT071 Results at EHA 2024 carsgen.com ↗
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association (“EHA”). |
| 2024-06-15 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 carsgen.com ↗
The overall response rate was 90%, including 5 patients (50%) with stringent complete response (sCR), 2 patients (20%) with very good partial response (VGPR), and 2 patients (20%) with partial response (PR). |
| 2023-12-04 | CARsgen Therapeutics Co., Ltd. | Regulatory CARsgen’s CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia carsgen.com ↗
the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for CT071 |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT071 | “CT071 is a fully human, autologous, chimeric antigen receptor (CAR) T-cell therapy directed against G protein-coupled receptor class C group 5 member D (GPRC5D), with expedited...” PMID 41062204 ↗ Oct 20252“Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma” NCT06407947 ↗ |
| Modality | Cell therapy | “autologous CAR T-cell therapy targeting GPRC5D” NCT06333509 ↗ |
| Target | GPRC5D | “targeting GPRC5D” NCT06333509 ↗ |